Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd. - Common Shares (NQ: CYTO )

0.3001 UNCHANGED
Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Altamira Therapeutics Ltd. - Common Shares

< Previous 1 2 3 4 Next >
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
HAMILTON, BERMUDA / ACCESSWIRE / March 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
HAMILTON, BERMUDA / ACCESSWIRE / March 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
- Nuance Pharma to develop and commercialize Bentrio™ nasal spray in Chinese Mainland, Hong Kong, Macau and South Korea - Altamira to receive up to $23.5 million in upfront and milestone payments... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo
- 75 patients randomized in Part B of study to receive either intranasal betahistine or placebo - Top-line results from the trial expected to be announced in Q2-2022 HAMILTON, BERMUDA / ACCESSWIRE /... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
- Dedicated unit to support Altamira's activities in consumer health products - OTC Consumer Health to be led by experienced marketing strategist, Jean Lachance HAMILTON, BERMUDA / ACCESSWIRE /... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Update on RNA Therapeutics Program
- Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeutics - Receipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference
HAMILTON, BERMUDA / ACCESSWIRE / January 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Update on Bentrio Program
- Bentrio™ becoming available through Amazon platform in key German market - Definite Marketing and Distribution Agreement signed for six Asian countries - Preparations for COVID-19 trial advancing -... 
From Altamira Therapeutics
Via AccessWire
Exposures COVID-19
Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy
HAMILTON, BERMUDA / ACCESSWIRE / December 16, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis
HAMILTON, BERMUDA / ACCESSWIRE / December 1, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021
- Altamira's peptide-based platform for extrahepatic RNA delivery shows promising results in management of abdominal aortic aneurysm in murine disease models - siRNA polyplexes targeting NF-kB suppress... 
From Altamira Therapeutics
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant
- Significant reduction of infectious viral titer in human nasal epithelium model with either prophylactic or therapeutic application - Results provide further confirmation for broad applicability in... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics and Wellesta Collaborate for Marketing and Distribution of Bentrio in Six Key Asian Markets
HAMILTON, BERMUDA / ACCESSWIRE / October 25, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application
HAMILTON, BERMUDA / ACCESSWIRE / October 14, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Product Safety
Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference
HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Update on Bentrio Program
- Building Bentrio™ brand and expanding in European markets - 510(k) premarket notification for allergy indication submitted to the U.S. Food and Drug Administration ("FDA") - Distributors signed up... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program
HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral... 
From Altamira Therapeutics
Via AccessWire
Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results
- Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 - Enrollment in Phase 2 trial of AM-125... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)
- Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p<0.01) - New data demonstrate protective effects in viral infections... 
From Altamira Therapeutics
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures Death Intellectual Property Legal
Altamira Therapeutics Announces Launch of Website Dedicated to Bentrio(TM) Nasal Spray
HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection... 
From Altamira Therapeutics
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.